



August 1, 2017

Arbutus Announces Conference Call to Provide a Corporate Update and Second Quarter 2017 Financial Results

VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, August 3, 2017 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss second quarter 2017 financial results and provide a corporate update.

To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 63313299.

About Arbutus

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.

Contact Information

Investors

Adam Cutler

Senior Vice President, Corporate Affairs

Phone: 604-419-3200

Email: acutler@arbutusbio.com

Tiffany Tolmie

Manager, Investor Relations

Phone: 604-419-3200

Email: ttolmie@arbutusbio.com

Media

David Schull

Russo Partners

Phone: 858-717-2310

Email: david.schull@russopartnersllc.com